Revlimid for Hodgkin’s
Although there is some evidence supporting (lenalidomide)Revlmid for non-Hodgkin’s Lymphoma, there is much less evidence for Hodgkin’s lymphoma. A recent phase II study in 38 patients with Hodgkin;s suggested that lenalidomide was well tolerated, and the most common grade serious toxicities were low white counts (47%), anemia (29%), and low platelets (18%). Four patients discontinued lenalidomide because of rash, elevated liver tests, and low blood counts. It concluded that the study provides preliminary evidence of lenalidomide’s activity in patients with relapsed and refractory non-Hodgkin’s lymphoma, and therefore exploration of lenalidomide in combination with other active agents is warranted. Several other small studies have come to similar conclusions. Several phase II studies are exploring activity of lenalidomide by itself or in combination.
For Professional version see here